Free tools, free alerts. Create a free account to get sector-matched alerts and save your searches.
Create free account →
2026-09-04

Regulatory Watch

AI-synthesized intelligence from CBN, FIRS, CAC, NAFDAC, SON, and NEPZA — so your business stays ahead of regulatory change.

September 4, 2026 6 updates 2 sources
NAFDAC has issued multiple alerts regarding substandard, counterfeit, and potentially harmful products, including blacklisting a UK supplier and placing a local company's products on watchlist. These actions signal heightened enforcement and the need for SMBs in the pharmaceutical and consumer goods sectors to verify product authenticity and ensure compliance to avoid legal and reputational risks.
What's being regulated
Pharmaceuticals Consumer Goods Healthcare Import/Export Distribution
Latest regulatory changes
Public Notice on Blacklisting Ayrtons Saunders Ltd, Uk
NAFDAC
NAFDAC blacklists Ayrtons Saunders Ltd, UK, and informs stakeholders about the action.
SMBs must avoid importing or distributing products from this company to prevent regulatory action.
Public Alert No. 043/2026-NAFDAC Places Products Marketed by Mofus Nigeria Ltd on Watchlist Pending Regulatory Investigation
NAFDAC
NAFDAC places products marketed by Mofus Nigeria Ltd on watchlist pending investigation.
SMBs dealing with Mofus Nigeria Ltd should verify product status and prepare for potential recalls or suspensions.
Public Alert No. 042/2026-Alert on the Seizure of Suspected Substandard and Falsified BPPL Artemether/Lumefantrine 80mg/480mg
NAFDAC
NAFDAC alerts on seizure of suspected substandard and falsified antimalarial medicine.
SMBs in pharmaceutical distribution must ensure their stock is authentic and from verified sources to avoid penalties.
Public Alert No. 041/2026 – Alert on Suspected Counterfeit ORACIRE+ Toothpaste
NAFDAC
NAFDAC warns of counterfeit ORACIRE+ toothpaste circulating as ORACARE+.
SMBs in consumer goods must check product authenticity and report suspicious items to NAFDAC.
Public Alert No: 039/2026 – Alert on the Risk of Drug Poisoning Associated with Concurrent Use of Gabapentinoids and Other Medicines
NAFDAC
NAFDAC warns about drug poisoning risks when gabapentinoids are used with other medicines.
SMBs in healthcare should educate customers and ensure proper labeling and dispensing practices.
CAC About to Ruin Distrifoods' 15-Year-Old Business After Assigning Same Registration Details to Other Entities - FIJ NG
Other
CAC allegedly assigned same registration details to other entities, threatening Distrifoods' business.
SMBs should verify their CAC registrations and monitor for potential conflicts to protect their business identity.
What this means for your business
Increased regulatory vigilance on product quality and authenticity.
Potential supply chain disruptions due to blacklisting and watchlists.
Need for robust due diligence on suppliers and products.
Importance of maintaining accurate registration and compliance records.
What to do next
1 Review and verify all product sources against NAFDAC alerts.
2 Implement internal quality checks for pharmaceuticals and consumer goods.
3 Stay updated with NAFDAC public notices and alerts.
4 Ensure CAC registrations are accurate and monitor for any discrepancies.
5 Train staff on identifying counterfeit products and reporting mechanisms.
← Previous edition
Browse archive
Next edition →

Never miss a regulatory change

From CBN monetary policy to FIRS tax circulars — our AI Workspace monitors the regulatory landscape so you don't have to.

Create free account